JAZZ - Jazz Pharmaceuticals plc Stock Analysis

Stock Taper

OPPORTUNITY RADAR SCREENER COMPARE ANY 2 STOCKS

JAZZ

JAZZ PHARMACEUTICALS PLC

NASDAQ

$222.45

▼ DOWN 3.78% (-8.74)

KEY STATISTICS

Market Cap$13.99 B

52w High$266.38

52w Low$128.80

Dividend Yield—

Frequency—

P/E8.29

Volume1.20M

Shares Out.62.82M

COMPANY

LEADERSHIP

CHIEF EXECUTIVE

Renee D. Gala

COMPENSATION 2026

Salary$884,789

Stock Awards$4,855,123

Incentive Plan Pay$0

All Other Comp.$82,441

Total$18,834,836

ABOUT

SECTOR

Healthcare

WENT PUBLIC

June 1, 2007

METHOD OF GOING PUBLIC

IPO

FULL TIME EMPLOYEES

2,890

PRICE TARGET

Target High$337.00

Target Low$229.00

Target Median$300.00

Target Consensus$292.80

UPCOMING EARNINGS

DateNov 4, 2026

DayWednesday

Rev. Est.$1.21B

NOV

WED

ETFS HOLDING THIS STOCK

ETFS HOLDING

340

LISTED HERE

RANKED BY POSITION SIZE

INSTITUTIONAL OWNERSHIP

SHARES OWNED

52.10%

HOLDERS

947

TOP 8 OF 947 · RANKED BY POSITION SIZE

Dimensional Fund Advisors LP

2.8M sh

$373.86M

Capital World Investors

Franklin Resources Inc

2.0M sh

$491.64M

PRICE

$222.45 ▼ DOWN 3.78% (−$8.74)

About Jazz Pharmaceuticals plc

https://www.jazzpharma.com ↗

Jazz Pharmaceuticals develops and commercializes neuroscience and oncology products worldwide, including treatments for sleep disorders, narcolepsy, leukemia, and solid tumors.

INDUSTRY

Biotechnology

A PRODUCT JAZZ PHARMACEUTICALS PLC IS KNOWN FOR

Ziihera® (zanidatamab-hrii)

Ziihera, a bispecific antibody approved in 2024 for HER2-positive biliary tract cancer, marks Jazz Pharmaceuticals' strategic shift into oncology with significant future growth potential.

COMPETITORS

COMPETITOR

Jazz Pharmaceuticals in 2025

SENTIMENT: + POSITIVE

INNOVATION · Q4 2025

Jazz Pharmaceuticals' Ziihera Shows Positive Phase 3 Results, Challenging Standard of Care in Gastroesophageal Adenocarcinoma

In late 2025, Jazz Pharmaceuticals announced positive top-line results from the Phase 3 HERIZON-GEA-01 clinical trial for Ziihera (zanidatamab). The study, evaluating the drug as a first-line treatment for patients with HER2-positive gastroesophageal adenocarcinoma (GEA), showed that Ziihera bested the current standard-of-care, Herceptin. This outcome was a significant clinical milestone, positioning Ziihera as a potential new standard of care and a major future revenue driver for the company.

ACQUISITION · MARCH 2025 · COMPLETED

Jazz Pharmaceuticals Acquires Chimerix for $935 Million, Bolstering Oncology Pipeline with Late-Stage Brain Cancer Drug

Jazz Pharmaceuticals completed its acquisition of Chimerix in April 2025 for approximately $935 million in cash. This strategic move significantly enhances Jazz's oncology portfolio by adding dordaviprone, a novel, first-in-class treatment for H3 K27M-mutant diffuse glioma, a rare and aggressive brain tumor, which had a PDUFA target action date of August 18, 2025.

Latest News

ZACKS INVESTMENT RESEARCH · OCT 6, 2026

Here's Why Jazz Pharmaceuticals (JAZZ) is a Strong Value Stock

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

READ ARTICLE

EARLIER COVERAGE

DEFENSE WORLD · OCT 5, 2026

Financial Comparison: Jazz Pharmaceuticals (NASDAQ:JAZZ) vs. vTv Therapeutics (NASDAQ:VTVT)

Jazz Pharmaceuticals (NASDAQ: JAZZ - Get Free Report) and vTv Therapeutics (NASDAQ: VTVT - Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, valuation, profitability, dividends and institutional ownership. Analyst Ratings This is a summary of current

READ ARTICLE